4.6 Article Proceedings Paper

Low-Level Laser Treatment Is Ineffective for Capsular Contracture: Results of the LaTCon Randomized Controlled Trial

期刊

PLASTIC AND RECONSTRUCTIVE SURGERY
卷 142, 期 5, 页码 621E-631E

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PRS.0000000000004826

关键词

-

类别

资金

  1. Sydney Vital implementation research pilot projects grant
  2. Cancer Institute NSW

向作者/读者索取更多资源

Background: Breast reconstruction with implants can be complicated by symptomatic capsular contracture, especially after radiotherapy. A phase I, nonrandomized clinical trial demonstrated improvement in capsular contracture and avoidance of revision surgery with low-level laser therapy. This phase II, double-blind, randomized controlled trial assessed the efficacy of low-level laser for treating capsular contracture in women with breast reconstruction following mastectomy for breast cancer. Methods: Participants had completed their definitive implant-based reconstruction a minimum of 6 months previously and were randomized to weekly treatments over 6 weeks with either an active or inactive low-level laser handpiece (Riancorp LTU-904). Pain, tightness, arm movement, and appearance were assessed by patient questionnaires. Breast symmetry, shape, naturalness, softness, and grade of contracture were assessed by clinician reports. Participants were assessed at 1 and 6 months after completion of the treatments. Results: A total of 42 patients (intervention arm, n = 20; placebo, n = 22) were assessed in the trial. Thirty-two had postmastectomy radiotherapy. There was no significant difference in the change in any patient-reported outcomes or clinician-reported outcomes of breast symmetry, shape, or naturalness for the two groups. There was a significantly greater improvement in clinician-reported breast softness (p < 0.05) and degree of contracture (p < 0.05) in the placebo group at both 1- and 6-month follow-up. Conclusion: Low-level laser is not an effective therapy for breast implant capsular contracture in reconstruction patients. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, I.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

Alexander C. J. van Akkooi, Tina J. Hieken, Elizabeth M. Burton, Charlotte Ariyan, Paolo A. Ascierto, Salvatore V. M. A. Asero, Christian U. Blank, Matthew S. Block, Genevieve M. Boland, Corrado Caraco, Sydney Chng, B. Scott Davidson, Joao Pedreira Duprat Neto, Mark B. Faries, Jeffrey E. Gershenwald, Dirk J. Grunhagen, David E. Gyorki, Dale Han, Andrew J. Hayes, Winan J. van Houdt, George C. Karakousis, Willem M. C. Klop, Georgina Long, Michael C. Lowe, Alexander M. Menzies, Roger Olofsson Bagge, Thomas E. Pennington, Piotr Rutkowski, Robyn P. M. Saw, Richard A. Scolyer, Kerwin F. Shannon, Vernon K. Sondak, Hussein Tawbi, Alessandro A. E. Testori, Mike T. Tetzlaff, John F. Thompson, Jonathan S. Zager, Charlotte L. Zuur, Jennifer A. Wargo, Andrew J. Spillane, Merrick Ross

Summary: Exciting advances in melanoma systemic therapies have provided opportunities for neoadjuvant systemic treatment in high-risk, resectable metastatic melanomas. This article presents the current state of neoadjuvant systemic therapy for melanoma, focusing on the surgical aspects and the role of surgical oncologists. It summarizes past developments in melanoma treatment and the evidence for neoadjuvant systemic therapy in stage III melanoma, discussing surgical issues, technical aspects, and other important considerations.

ANNALS OF SURGICAL ONCOLOGY (2022)

Article Oncology

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance

Felicity Newell, Ines Pires da Silva, Peter A. Johansson, Alexander M. Menzies, James S. Wilmott, Venkateswar Addala, Matteo S. Carlino, Helen Rizos, Katia Nones, Jarem J. Edwards, Vanessa Lakis, Stephen H. Kazakoff, Pamela Mukhopadhyay, Peter M. Ferguson, Conrad Leonard, Lambros T. Koufariotis, Scott Wood, Christian U. Blank, John F. Thompson, Andrew J. Spillane, Robyn P. M. Saw, Kerwin F. Shannon, John Pearson, Graham J. Mann, Nicholas K. Hayward, Richard A. Scolyer, Nicola Waddell, Georgina Long

Summary: This study examines the relationship between various factors and the response to immunotherapy in patients with advanced cutaneous melanoma. The results identify several factors associated with response and develop a multivariable model for predicting response. However, the study also indicates the presence of intratumor and intertumor heterogeneity in response to immunotherapy and the lack of clear biological mechanisms explaining non-predicted responses.

CANCER CELL (2022)

Article Oncology

Original Research Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients

Mary-Ann El Sharouni, Richard A. Scolyer, Carla H. van Gils, Sydney Ch'ng, Omgo E. Nieweg, Thomas E. Pennington, Robyn PM. Saw, Kerwin Shannon, Andrew Spillane, Jonathan Stretch, Arjen J. Witkamp, Vigfus Sigurdsson, John F. Thompson, Paul J. van Diest

Summary: This study examined whether the interval between diagnostic excision-biopsy and definitive wide excision with sentinel node biopsy (SNB) affected the size of SN metastatic deposits. The results showed that patients who underwent SNB later after diagnosis had significantly larger SN metastasis diameters. This finding has implications for management and prognosis.

EUROPEAN JOURNAL OF CANCER (2022)

Meeting Abstract Oncology

Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)

R. C. Simpson, M. Batten, E. R. Shanahan, I. Pires Da Silva, J. M. Versluis, I. L. M. Reijers, A. M. Menzies, R. P. M. Saw, M. Gonzalez, K. F. Shannon, A. J. Spillane, C. U. Blank, R. A. Scolyer, G. V. Long

ANNALS OF ONCOLOGY (2022)

Meeting Abstract Oncology

NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

G. V. Long, A. J. Spillane, T. E. Pennington, K. F. Shannon, J. Stretch, M. Gonzalez, R. P. M. Saw, S. N. Lo, R. A. Scolyer, A. M. Menzies

ANNALS OF ONCOLOGY (2022)

Editorial Material Oncology

ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases

Anna K. Lawless, David J. Coker, Serigne N. Lo, Tasnia Ahmed, Richard A. Scolyer, Sydney Ch'ng, Omgo E. Nieweg, Kerwin Shannon, Andrew Spillane, Jonathan R. Stretch, John F. Thompson, Robyn P. M. Saw

ANNALS OF SURGICAL ONCOLOGY (2022)

Letter Pathology

Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma

Elizabeth Paver, Karina Aivazian, Fiona Maclean, Georgina Long, Andrew J. Spillane, James S. Wilmott, Richard A. Scolyer

PATHOLOGY (2023)

Editorial Material Oncology

ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma

Trine Schoenfeldt, John F. Thompson, Serigne Lo, Krzysztof T. Drzewiecki, Jonathan Stretch, Robyn P. M. Saw, Andrew Spillane, Kerwin Shannon, Roger F. Uren, Annette H. Chakera, Omgo E. Nieweg

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Oncology

Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma

Trine Schoenfeldt, John F. Thompson, Serigne Lo, Krzysztof T. Drzewiecki, Jonathan Stretch, Robyn P. M. Saw, Andrew Spillane, Kerwin Shannon, Roger F. Uren, Annette H. Chakera, Omgo E. Nieweg

Summary: This study aimed to determine the clinical significance of sentinel nodes (SNs) in the triangular intermuscular space (TIS) in patients with melanoma. It found that 11% of patients with melanomas on their upper back had TIS SNs, and retrieval of these SNs was important for accurate staging and to minimize the risk of recurrence in the TIS.

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Surgery

Trends and variations in post-mastectomy breast reconstruction rates in Australia over 10 years

Nirmal Dayaratna, Chu Luan Nguyen, Andrew Spillane, Cindy Mak, Sanjay Kumar Warrier, Joseph R. Dusseldorp

Summary: The breast reconstruction rate in Australia has increased over the past decade, but significant variations still exist between different states. Reconstruction surgery is less common in older women and those living in remote areas. While the steady increase in reconstruction uptake is encouraging, existing barriers to equitable provision of reconstructive surgical services for all women with breast cancer still need to be addressed.

ANZ JOURNAL OF SURGERY (2023)

Article Immunology

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

Irene L. M. Reijers, Disha Rao, Judith M. Versluis, Alexander M. Menzies, Petros Dimitriadis, Michel W. Wouters, Andrew J. Spillane, Willem M. C. Klop, Annegien Broeks, Linda J. W. Bosch, Marta Lopez-Yurda, Winan J. van Houdt, Robert V. Rawson, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Sten Cornelissen, Jasper Bouwman, Joyce Sanders, Elsemieke Plasmeijer, Yannick S. Elshot, Richard A. Scolyer, Bart A. van de Wiel, Daniel S. Peeper, Alexander C. J. van Akkooi, Georgina V. Long, Christian U. Blank

Summary: The baseline IFN-gamma signature can be used to select patients who can benefit from anti-PD-1 monotherapy in the DONIMI trial. However, the addition of domatinostat, a class I HDAC inhibitor, does not provide additional benefits in patients receiving neoadjuvant anti-PD-1 +/- anti-CTLA-4. Neoadjuvant ipilimumab + nivolumab shows high pathologic response rates in stage III melanoma, but patients with low intra-tumoral IFN-gamma signatures are less likely to benefit.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Article Oncology

Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection

Lodewijka H. J. Holtkamp, Serigne N. Lo, John F. Thompson, Andrew J. Spillane, Jonathan R. Stretch, Robyn P. M. Saw, Kerwin F. Shannon, Omgo E. Nieweg, Angela M. Hong

Summary: This study evaluated the long-term node field control and survival of melanoma patients with node field recurrence following prior node dissection who underwent salvage surgery with adjuvant radiotherapy. The results showed that while adjuvant radiotherapy achieved control of the node field, disease progression at distant sites was common and the survival outcomes were poor.

JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Multidisciplinary Sciences

Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study

Brooke Nickel, Kirsten McCaffery, Jesse Jansen, Alexandra Barratt, Nehmat Houssami, Christobel Saunders, Andrew Spillane, Claudia Rutherford, Kirsty Stuart, Geraldine Robertson, Ann Dixon, Jolyn Hersch

Summary: Management of low-risk ductal carcinoma in situ (DCIS) is controversial, with clinical trials currently assessing the safety of active monitoring amidst concern about overtreatment. Women's understanding and views about low-risk DCIS and its management were explored through qualitative focus groups and brief quantitative questionnaires. The findings revealed limited prior awareness of DCIS, but substantial support for active monitoring as a management approach for low-risk DCIS, indicating the need for well-informed patient choice and potential future trials.

PLOS ONE (2023)

Review Public, Environmental & Occupational Health

Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis

Matthew N. Berger, Ellen S. Mowbray, Marian W. A. Farag, Erin Mathieu, Cristyn Davies, Claire Thomas, Robert Booy, Angus H. Forster, S. Rachel Skinner

Summary: Microarray patches (MAPs) show potential as a safe and effective method for vaccine delivery. They have been found to be well tolerated, with similar or enhanced immunogenicity compared to needle and syringe. Further research is needed to explore their full potential.

BMJ GLOBAL HEALTH (2023)

Article Public, Environmental & Occupational Health

Junior parkrun pilot in Australia: A real world evaluation

Erin Mathieu, Anne C. Grunseit, Bridget C. Foley, Lindsey J. Reece

Summary: The junior parkrun pilot in Australia has shown promise in encouraging children to engage in physical activity in a fun and inclusive way, with majority of parents acknowledging the benefits and enjoyment it brings to their children.

HEALTH PROMOTION JOURNAL OF AUSTRALIA (2023)

暂无数据